Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a
patient population that has limited ambulation, in a period of up to 144 weeks.